Wall Street Journal -- Capital efficiency is key for venture-backed start-ups, especially those health care companies engaging in costly clinical trials. SpineAlign Medical Inc., which has launched a medical device in Europe on just $13.6 million, shows that a lot can be done with relatively little capital.
